

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of :

Jagath KADURUGAMUWA, et al

Serial No.: 09/370,860

Filed: August 9, 1999

For: **NOVEL VACCINES AND
PHARMACEUTICAL
COMPOSITIONS USING
MEMBRANE VESICLES, AND
METHODS FOR PREPARING SAME**



) Examiner: not yet assigned

) Art Unit: 1643

RECEIVED

NOV 17 1999

TECH CENTER 1600/2900

New York, New York
November 11, 1999

INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Applicants wish to make of record the following documents (Form PTO-1449 is enclosed). Copies of these documents are not being submitted herewith, because each was made of record in the Parent Application Serial No. 08/691,484, filed August 2, 1996 to which the present application claims benefit under 37 U.S.C. §120. See, 37 C.F.R. 1.98(d).

U.S. PATENT DOCUMENTS

A1	4,394,448
A2	4,945,050
A3	4,971,801
A4	5,000,958
A5	5,186,941
A6	5,233,412
A7	5,242,947
A8	5,858,698

FOREIGN PATENT DOCUMENTS

B1 WO 95/23211
B2 WO 94/08021
B3 WO 91/11174
B4 WO 91/09616
B5 EP 0 061 253
B6 WO 92/05194
B7 WO 90/06696
B8 WO 93/22423
B9 WO 94/04677
B10 EP 0 564 689
B11 JP 43005011
B12 SU 1708351

OTHER DOCUMENTS

C1 Newland, et al., Vaccine, 10: 766-776 (1992).
C2 Mills et al., Vaccine, 6:116-122 (1988).
C3 Tijhaar et al., Vaccine, 12:1004-1011 (1994).
C4 Wills et al., J. of Virol., 68:6605-6618 (1994).
C5 Tan and Worobec, FEMS Microbial. Letts, 106:281-286 (1993).
C6 Bergmann et al., Infect. Immun., 57:2187-2195 (1989).
C7 Bernadsky et al., J. Bacteriol., 176:5225-5232 (1994).
C8 Kadurugamuwa et al., Antimicrob. Agents. Chemother., 37:715-721 (1993).
C9 Lightfoot and Lam, J. Bacteriol., 173:5624-5630 (1991).
C10 Martin and Beveridge, Antimicrob. Agents Chemother., 29:1079-1087 (1986).
C11 Rivera et al., J. Bacteriol., 170:512-521 (1988).
C12 Berk et al., Infect Immun., 55:1728-1730 (1987).
C13 Vasil et al., Antibiot. Chemother., 44:34-47 (1991).
C14 Ingram et al., Can J. Microbiol., 19:1407-1415 (1973).
C15 Poole and Hancock, FEMS Microbiol. Letts., 16:25-29 (1983).
C16 Hastie et al., Infect. Immun., 40:506-513 (1983).
C17 Kessler et al., J. Biol. Chem., 268:7503-7508 (1993).
C18 Lazdusniski et al., Biochemie, 72:147-156 (1990).
C19 Duoung et al., Gene 121:47-54 (1992).
C20 Guzzo et al., Infect. Immun., 60:510-517 (1992).
C21 Hamood et al., Infect. Immun., 60:510-517 (1992).
C22 Kadurugamuwa, et al., J. Bacteriol., 175:5798-5805 (1993).
C23 Kadurugamuwa, et al., Infect. Immun., 59:3463-3471 (1991).
C24 Beveridge, ASM News. 61:125-130 (1995).
C25 Guzman et al., Infect. Immun. 59:4391-4397 (1991).

- C26 Kadurugamuwa, et al., Abstract and Poster, 94th ASM, Las Vegas, May 23-27, 1994.
- C27 Kadurugamuwa, et al., Abstract, ICAAC, Orlando, Florida, October 4-7, 1994.
- C28 Kadurugamuwa, et al., Abstract and Poster, 95th ASM General Meeting, Washington, D.C., May 21-25, 1995.
- C29 Beveridge, CBDN Projects Annual Report, Group 2D August, 1993.
- C30 Kadurugamuwa, et al., J. Bacteriol., 177: 14, 3998-4008 (1995).

Applicants note that documents B11 and B12 are not in English. However, English language abstracts for both documents were submitted during prosecution of the parent application, and are not enclosed herewith.


Applicants request that these documents be considered by the Examiner before issuance of a first office action and made of record in this file. The Examiner is also asked to initial and return copies of the enclosed PTO-1449 forms to evidence such consideration.

This Information Disclosure Statement is being filed in accordance with the following provisions:


- ☒ CFR § 1.97(b) (3) Before the mailing date of a first Office Action on the merits. No fee is required.

If it is determined that a fee is required as set forth in 37 CFR § 1.17(p) or 1.17(i)(1), or if any additional fees are required, please charge such fee (or credit any overpayment) to Deposit Account No. 02-4467. A duplicate copy of this document is enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on November 11, 1999.


Kevin C. Hooper, Reg. No. 40,402

Respectfully submitted,

By: 
Kevin C. Hooper
Registration No. 40,402
BRYAN CAVE LLP
245 Park Avenue
New York, NY 10167-0034
(212) 692-1800